This study will address whether LBBaP is superior to RVAP in terms of safety and efficacy
Patients with AVB who meet indications for pacemaker
Implantation with an estimated percentage of ventricular pacing ≥50%
Ability to provide informed consent
Failure to cooperate with follow-up.
Persistent atrial fibrillation.
Patients with heart failure (LVEF) ≤35%,
Estimated glomerular filtration rate less than 30 ml/min.
. Patients with AVB who meet indications for pacemaker , with an estimated percentage of ventricular pacing ≥50%
Cohort
Prospective
Not listed
effectiveness with LBB pacing
Assess left ventricular global strain using speckle tracking echocardiography (percentage)
Incidence of adverse events in patient with LBB pacing
Malignant arrhythmia(Yes/No)
Incidence of septal perforation
Detect septal perforation(Yes/No)
Major Adverse Cardiovascular Events
• All-cause mortality (Yes or No) cardiovascular deaths (Yes or No) rehospitalisation with heart failure (Yes or No) Lead dislocation (Yes or No) Lead infection. (Yes or No)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
